PTC Therapeutics could boost revenue with vatiquinone for Friedreich's ataxia. Find out why PTCT stock is poised for growth ...

Citi analyst Geoff Meacham raised the firm’s price target on PTC Therapeutics (PTCT) to $50 from $46 and keeps a Sell rating on the shares ...

Fintel reports that on March 11, 2025, B of A Securities upgraded their outlook for PTC Therapeutics (NasdaqGS:PTCT) from ...

Bank of America upgraded shares of PTC Therapeutics (NASDAQ:PTCT – Free Report) from an underperform rating to a neutral ...

BofA analyst Tazeen Ahmad upgraded PTC Therapeutics (PTCT) to Neutral from Underperform with a price target of $55, up from $41. The firm ...

Analysts at Cantor Fitzgerald upped their FY2025 earnings per share (EPS) estimates for shares of PTC Therapeutics in a ...

Citi has expanded its biopharmaceutical research coverage, initiating coverage on seven small- and mid-cap (SMid) biotechnology companies. Citi said SMid biotechs remain an attractive alternative to ...

On Friday, Scotiabank (TSX:BNS) initiated coverage on PTC Therapeutics (NASDAQ:PTCT) shares, assigning a Sector Perform rating and establishing a price target of $55.00. The coverage by Scotiabank ...

Under the terms of the agreement, Kyorin will receive $55m upfront and will be eligible for milestone payments of up to ...